Leuprorelin (CAS 53714-56-0) is a high-purity LHRH agonist API, designed for the treatment of hormone-dependent cancers and diseases. With a precise peptide molecular structure, it acts as a potent GnRH receptor agonist, initially stimulating the secretion of LH and FSH, which in turn leads to a rapid and sustained increase in testosterone and estradiol levels.
However, through a process known as receptor desensitization, prolonged administration of Leuprorelin results in the downregulation of pituitary GnRH receptors, leading to a profound and sustained depletion of gonadotropin secretion. This ultimately causes a significant reduction in testosterone and estradiol production, effectively starving androgen-dependent tumors like prostate cancer and estrogen-dependent tumors like breast cancer of their growth-promoting hormone.
Produced under stringent GMP standards, this API ensures consistent purity, high potency, and batch-to-batch stability, making it an ideal raw material for pharmaceutical formulation. It is widely used in the development of injectable formulations for the treatment of castration-resistant prostate cancer, endometrial endometriosis, and other hormone-responsive malignancies, catering to the needs of pharmaceutical manufacturers and research institutions.
